flow cytometry

1:33
Characterization of the immune impact of DARA by mass cytometry in multiple myeloma
Gareth Morgan
2:11
Mass spectrometry-flow cytometry study of IgM MGUS progression to Waldenström’s
Jonas Paludo
3:42
MRD detection in myeloma autografts: 8-colour flow cytometry or NGS?
Hiroyuki Takamatsu
3:23
The definitive guide to multiple myeloma at ASH 2018: part III
Mohamad Mohty et al.
1:28
Flow cytometry vs. NGS testing for determining MRD negativity in patients with ALL
Stephan Grupp
2:06
Identifying relapse in B-ALL patients treated with tisagenlecleucel using MRD
Stephan Grupp
2:34
MRD in CLL: utility from trials to individuals
John Seymour
1:11
Let me introduce you to ERIC: the European Research Initiative on CLL
Paolo Ghia
1:25
A perspective on MRD in CLL: treatment efficacy, early relapse detection & more
Eva Kimby
1:59
The expanding role of MRD in CLL
Florence Cymbalista
1:09
Novel ventoclax combinations for CLL
Eva Kimby
1:16
Thoughts on the use of MRD in CLL
Daniel Catovsky
1:14
Where will we be in MM management 5 years from now?
Elena Zamagni
3:19
MRD detection in myeloma: approval of NGS assay & questions for the clinic
Kenneth Anderson
1:56
How do we define a ‘cure’ in myeloma?
Annemiek Broyl
2:48
MRD and disease eradication in myeloma
Jesús San Miguel
The content of VJHemOnc is intended for healthcare professionals